Publikationen von S. Sperl

Banke, I. J.; Arlt, M. J. E.; Mueller, M. M.; Sperl, S.; Stemberger, A.; Stürzebecher, J.; Amirkhosravi, A.; Moroder, L.; Kruger, A.: Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity. Thrombosis and Haemostasis 94 (5), S. 1084 - 1093 (2005)

Mueller, M. M.; Sperl, S.; Stürzebecher, J.; Bode, W.; Moroder, L.: (R)-3-amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode. Biological Chemistry 383 (7-8), S. 1185 - 1191 (2002)

De Prada, N. A.; Schroeck, F.; Sinner, E. K.; Mühlenweg, B.; Twellmeyer, J.; Sperl, S.; Wilhelm, O. G.; Schmitt, M.; Magdolen, V.: Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin - Characterization of different PAI-1 mutants. European Journal of Biochemistry 269 (1), S. 184 - 192 (2002)

Bürgle, M.; Sperl, S.; Stürzebecher, J.; Krüger, A.; Schmalix, W.; Kessler, H.; Moroder, L.; Magdolen, V.; Wilhelm, O.G.; Schmitt, M.: The urokinase-type plasminogen activator (uPA) system - A new target for tumor therapy. In: Proteinase and Peptidase Inhibiton: Recent Potential Targets for Drug Development, S. 231 - 248 (Hg. Smith, H.J.; Simons, C.). Taylor & Francis, London (2002)

Sperl, S.; Moroder, L.: Pyroglutamic acid peptides. In: Synthesis of Peptides and Peptidomimetics, S. 454 - 460 (Hg. Goodman, M.; Felix, A.; Moroder, L.; Toniolo, C.). Georg Thieme Verlag, Stuttgart (2002)